Finally, the specialized complexity of establishing specifications is daunting. As Koppel explains, even something ostensibly simple, such as blood-pressure measurement, can get dropped in translation due to the modifiers accompanying the figures: standing, seated, preinjection, labile, noncompliant. So imagine a common language for MRI reports or operative notes. Although industry influence is indisputable, such an description conflicts with the impression I acquired from Judy Faulkner, chief executive officer of EHR maker Epic Systems, who advocates for government-created standards. Whether or not other vendors are prepared to make their items interoperable, government frequently overrides industry’s financial passions to achieve a greater public good.4SC granted U.S. Patent for medication to treat rheumatoid arthritis Martinsried-based drug discovery and development firm 4SC AG announced today that the united states Patent and Trademark Office has granted the patent with the US patent #7 7,176,241 for its drug candidate SC12267. This patent protects the DHODH inhibitor that is used by 4SC to treat rheumatoid arthritis and is currently undergoing testing in scientific phase IIa. Furthermore, the patent also addresses further back-up substances linked to SC12267, medical formulations and the treatment of patients with SC12267. The patent shall apply until 2020. Related StoriesUniversity of Manchester scientists identify brain mechanism that raises pain thresholdArthritis individuals to be better contributors to medical guideline developmentScientists identify brand-new protein that regulates intensity of tissue damage caused by RAThe patent is component of a portfolio of patents taken out by 4SC AG for SC12267 and a group of chemically related DHODH inhibitors.